Press Releases

Press Releases

CEO Shawn Singh to lead discussion on the future of mental health solutions SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 26, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,
Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen’s Board of Directors the option to implement a future reverse stock split of the Company’s issued and outstanding common stock, if necessary to maintain the Company’s listing on the Nasdaq Capital Market, and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 6, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 3, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that
Goldie Hawn to lead discussion on supporting mental health around the globe with preeminent C-suite executives, politicians, nonprofit leaders and entrepreneurs on the importance of mental health SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 20, 2022-- Vistagen (Nasdaq: VTGN), a late
In healthy subjects, intranasal administration of PH94B activated nasal chemosensory cells, rapidly reduced sympathetic tone, and provided rapid self-reported calmness SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 19, 2022-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 9, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous
Independent biostatisticians recommend continuing PALISADE-2 without any changes after conducting interim analysis of 140 completed subjects Topline data for PALISADE-2 trial expected in the first half of 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc.
Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 begins Preliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 9, 2022-- VistaGen Therapeutics, Inc . (NASDAQ: VTGN) a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today
Displaying 11 - 20 of 217